Medicare Enrolled
Dr. Robert Goldklang, M.D.
Gastroenterology · Encinitas, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Goldklang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Goldklang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Goldklang
Dr. Robert Goldklang is a gastroenterology specialist in Encinitas, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Goldklang performed 9,383 Medicare services across 1,870 unique beneficiaries.
Between the years covered by Open Payments, Dr. Goldklang received a total of $27,234 from 59 pharmaceutical and/or device companies across 739 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Goldklang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 1% volume in CA
$27,234 industry payments
Medicare Practice Summary
Medicare Utilization ↗9,383
Medicare services
Top 1% in CA for gastroenterology
1,870
Unique beneficiaries
$39
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~469 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
6,600 | $17 | $80 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
864 | $51 | $298 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
343 | $73 | $440 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
271 | $107 | $599 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
203 | $71 | $1,013 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
194 | $84 | $537 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
139 | $206 | $753 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
133 | $117 | $1,472 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
105 | $107 | $566 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
92 | $146 | $1,084 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
85 | $188 | $1,200 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
63 | $131 | $780 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
49 | $65 | $159 |
| Balloon dilation of esophagus, stomach, or upper small bowel, less than 3.0 cm A procedure using a flexible endoscope to widen a narrowed section of the esophagus, stomach, or upper small bowel with a balloon that is less than 3.0 cm in length. |
44 | $101 | $3,746 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
43 | $188 | $1,170 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
39 | $58 | $335 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
37 | $80 | $908 |
| External hemorrhoid removal by rubber banding A procedure to remove external hemorrhoids using rubber bands to cut off blood supply. The affected tissue is tied off and eventually falls off. |
28 | $242 | $1,420 |
| Dilation of esophagus | 22 | $33 | $535 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $143 | $543 |
| Endoscopic removal of bile or pancreatic duct stone A flexible endoscope is used to remove stones or debris from the bile or pancreatic ducts. |
14 | $183 | $1,180 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
70.8% high complexity
6.3% medium
22.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,234
Total received (2018-2024)
Avg $3,891/year across 7 years
Top 10% in CA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
739
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,750 (57.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$11,484 (42.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,733
2023
$2,830
2022
$2,594
2021
$2,338
2020
$1,158
2019
$1,648
2018
$13,933
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$799
Takeda Pharmaceuticals U.S.A., Inc.
$457
Janssen Biotech, Inc.
$337
Phathom Pharmaceuticals, Inc.
$236
GENZYME CORPORATION
$134
Lilly USA, LLC
$110
PFIZER INC.
$105
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$94
Celltrion USA Inc.
$91
Intercept Pharmaceuticals, Inc.
$80
Celgene Corporation
$76
Regeneron Healthcare Solutions, Inc.
$50
Ferring Pharmaceuticals Inc.
$45
QOL Medical, LLC
$33
Madrigal Pharmaceuticals
$25
AIMMUNE THERAPEUTICS, INC.
$23
VIVUS LLC
$22
Exact Sciences Corporation
$18
Top 3 companies account for 58.3% of 2024 payments
All-time payments by company (2018-2024) ›
Horizon Pharma plc
$5,163
Synergy Pharmaceuticals Inc
$4,325
ABBVIE INC.
$2,478
Daiichi Sankyo Inc.
$1,964
Takeda Pharmaceuticals U.S.A., Inc.
$1,886
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$1,656
Janssen Biotech, Inc.
$1,488
AbbVie, Inc.
$807
AbbVie Inc.
$690
Celgene Corporation
$567
PFIZER INC.
$355
Ferring Pharmaceuticals Inc.
$354
GENZYME CORPORATION
$342
Janssen Scientific Affairs, LLC
$309
Regeneron Healthcare Solutions, Inc.
$238
UCB, Inc.
$238
Phathom Pharmaceuticals, Inc.
$236
QOL Medical, LLC
$234
Lucid Diagnostics Inc.
$199
Intercept Pharmaceuticals, Inc.
$182
Amgen Inc.
$181
Ironwood Pharmaceuticals, Inc
$176
IRONWOOD PHARMACEUTICALS, INC
$175
Braintree Laboratories, Inc.
$173
Micro-tech Endoscopy USA, Inc.
$168
Boston Scientific Corporation
$159
Merck Sharp & Dohme Corporation
$155
Allergan Inc.
$154
Merck Sharp & Dohme LLC
$150
Olympus America Inc.
$146
Lilly USA, LLC
$137
Exact Sciences Corporation
$128
Covidien LP
$118
Shionogi Inc
$118
INTERCEPT PHARMACEUTICALS, INC.
$108
Bayer HealthCare Pharmaceuticals Inc.
$103
Alfasigma USA, Inc.
$101
Avadel Specialty Pharmaceuticals, LLC
$101
Endogastric Solutions, Inc
$101
Nestle HealthCare Nutrition Inc.
$96
INTRA-SANA LABORATORIES
$96
Celltrion USA Inc.
$91
Echosens North America, Inc.
$89
Romark Laboratories, LC
$77
RedHill Biopharma Inc.
$58
AMAG Pharmaceuticals, Inc.
$46
Alnylam Pharmaceuticals Inc.
$46
Organon LLC
$38
EVOKE PHARMA, INC.
$32
Madrigal Pharmaceuticals
$25
Pharmacosmos Therapeutics Inc.
$25
Prometheus Laboratories Inc.
$24
AIMMUNE THERAPEUTICS, INC.
$23
NESTLE HEALTHCARE NUTRITION INC.
$22
VIVUS LLC
$22
Gilead Sciences, Inc.
$20
Ardelyx, Inc.
$16
VIVUS, Inc.
$14
Napo Pharmaceuticals Inc
$9
Top 3 companies account for 43.9% of all-time payments
Associated products mentioned in payments ›
AVSOLA · Alinia · Amitiza · BF · BRUSHES · Balloon · Bravo · CIMZIA · CLENPIQ · CREON · CS · Cimzia · Cologuard Collection Kit · Creon · Cytology · DIFICID · DUPIXENT · Dexilant · ENTYVIO · ESOPHYX · Entyvio · FERAHEME · Fibroscan · GATTEX · GIMOTI · GIVLAARI · HUMIRA · Humira · IBSRELA · INFLECTRA · INJECTAFER · LINZESS · Linzess · MAVYRET · MOTEGRITY · MOTOFEN · Mavyret · Monoferric · Motegrity · Movantik · Mulpleta · Mytesi · Noctiva · OCALIVA · OMVOH · PANCREAZE · PREPOPIK · PRIMARY CARE - DISEASE STATE · QSYMIA · REBYOTA · RELTONE 200 MG · REMICADE · RENFLEXIS · RESMETIROM · RINVOQ · SC · SKYRIZI · STELARA · SUCRAID · SUPREP · SUPREP BOWEL PREP · SUTAB · Sucraid · TREMFYA · TRULANCE · Talicia · Trulance · UCERIS · VEGZELMA · VIBERZI · VOQUEZNA · VRAYLAR · Wision EndoScreener · XARELTO · XELJANZ · XENON LAMP · XIFAXAN · XIFAXANIBSD · Xofigo · ZENPEP · ZEPATIER · ZEPOSIA · ZYMFENTRA · Zelnorm
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (58%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 10% for gastroenterology in CA.
Geographic Context
Gastroenterologists within 10 mi
149
Per 100K population
4.5
County median income
$102,285
Nearest hospital
SCRIPPS MEMORIAL HOSPITAL - ENCINITAS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Goldklang is a clinical cardiology specialist, with above-average Medicare volume (top 1% in CA), with low-engagement industry engagement in the top 10% of CA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Goldklang experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Goldklang performed 6,600 vedolizumab infusion (entyvio) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Goldklang receive payments from pharmaceutical companies?
Yes. Dr. Goldklang received a total of $27,234 from 59 companies across 739 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Goldklang's costs compare to other gastroenterologists in Encinitas?
Dr. Goldklang's average Medicare payment per service is $39. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Goldklang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Encinitas
Browse gastroenterologists in Encinitas ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in CA
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in CA
Which CA gastroenterologists receive the most from drug and device companies.
By company
Horizon Pharma plc Payments to Doctors
See all physicians who received payments from Horizon Pharma plc.
By company
Synergy Pharmaceuticals Inc Payments to Doctors
See all physicians who received payments from Synergy Pharmaceuticals Inc.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology